SEC Form 4 · accession 0001209191-19-004240
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Palczuk
Officer — Chief Operating Officer
Period of report
Jan 16, 2019
Accepted (ET)
Jan 17, 2019 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 16, 2019 | P | 3,000 | $10.53 | A | 8,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.40 to $10.659, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2Consists of 3,000 shares of common stock held by Ms. Palczuk and 5,500 shares of common stock held by Ms. Palczuk jointly with her spouse.